July 2022

2021 PRMRP-Awarded Research Grants

In 2020, Congress for the first time included “peripheral neuropathy” as an eligible condition for study through a $370 million fund administered by the Department of Defense (DoD) known as the “Peer Reviewed Medical Research Program (PRMRP).” This important breakthrough was a direct result of the nationwide advocacy of the peripheral neuropathy community, led by FPN.

This accomplishment has allowed our research community to apply for funding from a federal program to which they previously did not have access. 

Every year, Congress determines the conditions that are eligible for study through the PRMRP by listing them in the Senate version of the annual Defense Appropriations Act.

Here are the peripheral neuropathy-related projects that will receive funding as part of the 2021 bill.

Peripheral Neuropathy Advocacy

Help Gregory and FPN Cross the Finish Line!

Gregory Maassen is so close to the end of his e-bike tour across the U.S. Won’t you help in achieving his goals of completing his cross-country tour in San Francisco on August 2, and raising $150,000 for FPN?

Click here to support Gregory and click here to learn more about his journey.

Chronic Pain in the Summer

A nice and easy read from Practical Pain Management on how you can have fun in the sun this summer, even if you have chronic pain.

Read now.

Join The Speak for Your Feet Contest!

Share your voice today to help support more productive conversations regarding diabetes and associated nerve pain. Create a memory aid (mnemonic) that encourages people suffering from diabetic nerve pain of the feet to discuss symptoms, important healthcare reminders and potential treatment solutions with their physicians! 

Click here.

Webinar Recordings Now Available!

For those who missed our live programs on anti-MAG peripheral neuropathy and Small Fiber Neuropathy, please click here to gain access to the recordings and related materials.

FDA Approves Vutrisiran to Treat hATTR Amyloidosis

The approval was based off results from the phase 3 HELIOS-A study, which showed that vutrisiran met its primary end point of change in modified Neuropathy Impairment Score + 7 over a nine-month treatment period.

Read more.

The Foundation for Peripheral Neuropathy provides education and support today as we walk toward a cure for tomorrow.

Support us in advancing a cure!

FPN is a non-profit organization that is solely funded by our readers.

Donate Now!